Crovalimab

Therapeutic indications

Crovalimab is indicated for:

Paroxysmal nocturnal hemoglobinuria

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Crovalimab as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):

In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

One loading dose administered by intravenous infusion on Day 1, followed by four additional loading doses administered by subcutaneous injection on Days 2, 8, 15, and 22, and thereafter maintenance doses administered by subcutaneous injection on Day 29 and every 4 weeks

Contraindications

Crovalimab is contraindicated in the following cases:

Lactation

Neisseria meningitidis infection

Meningococcal infectious disease

Patients unvaccinated against Neisseria meningitidis

not Meningococcal vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.